

29 Mar 2018 | **News**

QUOTED. March 29, 2018. Oliver Schacht.

by

Check out what Curetis NV CEO Oliver Schacht had to say about the novel nature of US FDA's ongoing review of the firm's multiplex molecular respiratory infection diagnostic.

"FDA ... at peak times, had up to 14 reviewers working on this submission, which [it] certainly hinted at as being one of the most complex submissions it has seen." –Oliver Schacht, CEO, Curetis NV

- Find out more: [Could First-Mover Advantage Make Curetis Ripe For The Picking By Dx Players?](#)

[Click here](#) for a free trial of *Medtech Insight*